Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5′-monophosphate-activated protein kinase

Diabetes, Obesity and Metabolism

Volumn 15, Issue 12, 2013, Pages 1128-1135

  Ikegami, M ^a   Ikeda, H ^a   Ohashi, T ^a   Ohsawa, M ^a   Ishikawa, Y ^a   Kai, M ^a   Kamei, A ^b   Kamei, J ^a  

^a HOSHI UNIVERSITY   (Japan)

^b Mine Pharmacy   (Japan)

Author keywords

Energy regulation; Gluconeogenesis; Glycogenolysis; Liver; Neuropharmacology; Pharmacology

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6 [4 (2 PIPERIDIN 1 YLETHOXY)PHENYL] 3 PYRIDIN 4 YLPYRAZOLO[1,5 A]PYRIMIDINE; ADENOSINE PHOSPHATE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLYCOLYTIC ENZYME; MESSENGER RNA; OLANZAPINE; PROPRANOLOL; PYRIMIDINE DERIVATIVE; PYRUVIC ACID; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HYPERGLYCEMIA; HYPOTHALAMUS; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ENERGY REGULATION; GLUCONEOGENESIS; GLYCOGENOLYSIS; LIVER; NEUROPHARMACOLOGY; PHARMACOLOGY;

ADRENERGIC BETA-ANTAGONISTS; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; ENZYMES; HOMEOSTASIS; HYPOTHALAMUS; LIVER; MALE; MICE; PHOSPHORYLATION; PROPRANOLOL; PROTEIN KINASE INHIBITORS; PYRUVIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84887156474     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12148     Document Type: Article

References (40)

1. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996; 124: 159-167.
2. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111-123.
3. Tollefson GD, Beasley CM Jr, Tran PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457-465.
4. Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2013; 16: 1205-1218.
5. McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32.
6. Meyer J, Koro CE, L'Italien GJ. The metabolic syndrome and schizophrenia: a review. Int Rev Psychiatry 2005; 17: 173-180.
7. De Hert MA, van Winkel R, Van Eyck D et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006; 83: 87-93.
8. Sernyak MJ, Gulanski B, Rosenheck R. Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. J Clin Psychiatry 2005; 66: 1463-1467.
9. Hanwella R, de Silva V, Wijeratne C, Ketharanathan T, de Silva J. Clozapine-associated weight loss. J Psychopharmacol 2010; 24: 1127-1129.
10. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22: 841-852.
11. Boyda HN, Tse L, Procyshyn RM et al. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 945-954.
12. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007; 32: 289-297.
13. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 2004; 29: 18-24.
14. Kim MS, Lee KU. Role of hypothalamic 5'-AMP-activated protein kinase in the regulation of food intake and energy homeostasis. J Mol Med 2005; 83: 514-520.
15. Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006; 116: 1776-1783.
16. Ramamurthy S, Ronnett GV. Developing a head for energy sensing: AMP-activated protein kinase as a multifunctional metabolic sensor in the brain. J Physiol 2006; 574: 85-93.
17. Turnley AM, Stapleton D, Mann RJ, Witters LA, Kemp BE, Bartlett PF. Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system. J Neurochem 1999; 72: 1707-1716.
18. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15-25.
19. McCrimmon RJ, Fan X, Ding Y, Zhu W, Jacob RJ, Sherwin RS. Potential role for AMP-activated protein kinase in hypoglycemia sensing in the ventromedial hypothalamus. Diabetes 2004; 53: 1953-1958.
20. Yang CS, Lam CKL, Chari M et al. Hypothalamic AMP-activated protein kinase regulates glucose production. Diabetes 2010; 59: 2435-2443.
21. 1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 2007; 104: 3456-3459.
22. Nordlie RC, Foste JD, Lange AJ. Regulation of glucose production by the liver. Annu Rev Nutr 1999; 19: 379-406.
23. Pilkis SJ, Granner DK. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 1992; 54: 885-909.
24. Shimazu T. Neuronal regulation of hepatic glucose metabolism in mammals. Diabetes Metab Rev 1987; 3: 185-206.
25. Uyama N, Geerts A, Reynaert H. Neural connections between the hypothalamus and the liver. Anat Rec 2004; 280A: 808-820.
26. Shimazu T, Ogasawara S. Effects of hypothalamic stimulation on gluconeogenesis and glycolysis in rat liver. Am J Physiol 1975; 228: 1787-1793.
27. Haley MJ, McCormic WG. Pharmacological effects produced by intracerebral injections of drug in the conscious mice. Br J Pharmacol 1957; 12: 12-15.
28. Ohsawa M, Carlsson A, Asato M et al. The dipeptide Phe-Phe amide attenuates signs of hyperalgesia, allodynia and nociception in diabetic mice using a mechanism involving the sigma receptor system. Mol Pain 2011; 7: 85.
29. Hedenmalm K, Hägg S, Ståhl M, Mortimer Ö, Spigset O. Glucose intolerance with atypical antipsychotics. Drug Saf 2002; 25: 1107-1116.
30. Holt RI, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004; 21: 515-523.
31. Sacher J, Mossaheb N, Spindelegger C et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 2008; 33: 1633-1641.
32. Barthel A, Schmoll D. Novel concepts in insulin regulation of hepatic gluconeogenesis. Am J Physiol Endocrinol Metab 2003; 285: E685-692.
33. Streeper RS, Svitek CA, Chapman S, Greenbaum LE, Taub R, O'Brien RM. A multicomponent insulin response sequence mediates a strong repression of mouse glucose-6-phosphatase gene transcription by insulin. J Biol Chem 1997; 272: 11698-11701.
34. Kahn A. Transcriptional regulation by glucose in the liver. Biochimie 1997; 79: 113-118.
35. Trinh KY, O'Doherty RM, Anderson P, Lange AJ, Newgard CB. Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. J Biol Chem 1998; 273: 31615-31620.
36. Minokoshi Y, Alquier T, Furukawa N et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004; 428: 569-574.
37. Kawai Y, Arinze IJ. Beta-adrenergic receptors in rabbit liver plasma membranes. Predominance of beta 2-receptors and mediation of adrenergic regulation of hepatic glycogenolysis. J Biol Chem 1983; 258: 4364-4371.
38. Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucoseintolerant state in hamsters. Neuroendocrinology 1999; 69: 160-166.
39. Zhou L, Sutton GM, Rochford JJ et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab 2007; 6: 398-405.
40. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes 2001; 50: 376-384.